KV Pharmaceutical Smacked With Class-Action Lawsuit
Categories: Bidness, See You in Court!
 |
| Image via |
| Big beard, big problems: KV's former CEO Marc Hermelin |
The suit, filed yesterday in federal court, is being brought by folks who purchased KV stock last Spring. The plaintiffs allege that the company was less than up-front about its "financial well-being, business operations, and prospects" at that time.
Specifically, the plaintiffs claim, KV failed to disclose that the FDA hadn't granted the company exclusive distribution rights to Makena -- a hormone injection used by pregnant women to lower the risk of premature birth.
Nor, they allege, did KV level with investors about Makena's $1500 price tag per dosage, and how that would "decrease meaningful demand."
Check out the complaint below. Class Action Complaint v. KV Pharm
Email to Friend
Write to Editor
Print Article
